Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study -

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Information type: Randomised controlled trials
Source: The Lancet Infectious Diseases
Specialities: Infection and infectious diseases
Summary
In this RCT (n=1443) tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate for maintenance of virological suppression (97% vs 93%, difference = 4.1%, 95% CI 1.6% to 6.7%) after switching stable patients and led to improved bone mineral density and renal function
UKMi comment
Nephrotoxocity and reduction in bone mineral density are identified risks of tenofovir disoproxil fumarate. Tenofovir alafenamide is a reformulation which is being investigated for the potential to reduce the instance of these adverse effects without affecting efficacy.
Related links: